| | LDL-C | | | Variables | Quartile 1 (<1.74 mmol/L) | Quartile 2 (1.74–2.15 mmol/L) | Quartile 3 (2.15–2.67 mmol/L) | Quartile 4 (>2.67 mmol/L) | value |
| | Male, (%) | 701 (57.2) | 593 (49.6) | 542 (45.7) | 509 (42.6) | <0.001 | | Age, year | 60.6 ± 10.7 | 59.9 ± 10.6 | 59.5 ± 10.9 | 58.1 ± 11.2 | <0.001 | | BMI, kg/m2 | 24.3 ± 3.4 | 24.6 ± 3.3 | 24.7 ± 3.2 | 24.7 ± 3.4 | 0.285 | | HTN, (%) | 854 (69.7) | 845 (70.7) | 862 (72.6) | 767 (64.2) | 0.017 | | DM, (%) | 829 (67.6) | 624 (52.2) | 582 (49.0) | 602 (50.4) | <0.001 | | Insulin | 262 (21.4) | 178 (14.9) | 166 (14.0) | 176 (14.7) | <0.001 | | Oral medication | 769 (62.7) | 564 (47.2) | 499 (42.0) | 515 (43.1) | <0.001 | | Newly diagnosed | 40 (3.3) | 49 (4.1) | 66 (5.6) | 69 (5.8) | 0.001 | | CKD, (%) | 116 (9.5) | 114 (9.5) | 106 (8.9) | 111 (9.3) | 0.770 | | eGFR, mL/min | 92.2 ± 30.1 | 92.4 ± 29.1 | 90.4 ± 27.3 | 89.9 ± 27.1 | 0.102 | | HF, (%) | 73 (6.0) | 56 (4.7) | 52 (4.4) | 51 (4.3) | 0.051 | | Persistent AF, (%) | 41 (3.3) | 47 (3.9) | 44 (3.7) | 43 (3.6) | 0.815 | | Angina pectoris, (%) | 342 (27.9) | 353 (29.5) | 320 (27.0) | 277 (23.2) | 0.004 | | Chest pain, (%) | 302 (24.6) | 303 (25.3) | 279 (23.5) | 235 (19.7) | 0.002 | | Vasospastic angina, (%) | 40 (3.3) | 50 (4.2) | 41 (3.5) | 42 (3.5) | 0.978 |
| | Laboratory findings | | TC, mmol/L | 3.13 ± 0.47 | 3.65 ± 0.36 | 4.14 ± 0.36 | 5.21 ± 0.75 | <0.001 | | TG, mmol/L | 1.36 ± 1.02 | 1.39 ± 0.86 | 1.56 ± 0.95 | 1.83 ± 0.97 | <0.001 | | HDL-C, mmol/L | 1.30 ± 0.36 | 1.32 ± 0.31 | 1.35 ± 0.31 | 1.37 ± 0.34 | <0.001 | | LDL-C, mmol/L | 1.42 ± 0.26 | 1.94 ± 0.13 | 2.41 ± 0.16 | 3.37 ± 0.62 | <0.001 | | hsCRP, nmol/L | 31.43 ± 95.24 | 23.81 ± 79.05 | 24.76 ± 106.67 | 28.57 ± 89.53 | 0.156 | | Fasting glucose, mmol/L | 6.88 ± 2.05 | 6.66 ± 2.05 | 6.66 ± 2.11 | 6.83 ± 2.61 | 0.018 | | HbA1c, % | 6.9 ± 1.2 | 6.7 ± 1.2 | 6.7 ± 1.3 | 6.8 ± 1.3 | 0.002 | | Cr, μmol/L | 76.3 ± 83.9 | 76.3 ± 91.5 | 76.3 ± 91.5 | 76.3 ± 83.9 | 0.949 | | Lipoprotein (a), μmmol/L | 0.71 ± 0.71 | 0.93 ± 1.00 | 1.07 ± 1.07 | 1.25 ± 1.36 | <0.001 | | Apo A-I, g/L | 1.34 ± 0.28 | 1.41 ± 0.25 | 1.45 ± 0.22 | 1.49 ± 0.26 | <0.001 | | Apo B, g/L | 0.50 ± 0.10 | 0.62 ± 0.09 | 0.74 ± 0.10 | 0.95 ± 0.19 | <0.001 | | Apo C-II, g/L | 0.03 ± 0.01 | 0.04 ± 0.02 | 0.04 ± 0.02 | 0.05 ± 0.02 | <0.001 | | Apo E, g/L | 0.02 ± 0.018 | 0.03 ± 0.01 | 0.03 ± 0.01 | 0.04 ± 0.01 | <0.001 |
| | Type of statins | | | | | <0.001 | | Atorvastatin, (%) | 617 (50.3) | 650 (54.3) | 601 (50.6) | 535 (44.8) | | | Simvastatin, (%) | 251 (20.5) | 243 (20.3) | 243 (20.5) | 274 (22.9) | | | Rosuvastatin, (%) | 243 (19.8) | 175 (14.6) | 145 (12.2) | 191 (16.0) | | | Pitavastatin, (%) | 60 (4.9) | 70 (5.9%) | 103 (8.7%) | 88 (7.4) | | | Pravastatin, (%) | 25 (2.0) | 34 (2.8) | 51 (4.3) | 67 (5.6) | | | Fluvastatin, (%) | 30 (2.4) | 24 (2.0) | 44 (3.7) | 39 (3.3) | | | Follow-up, days | 1,639 ± 751 | 1,682 ± 769 | 1,792 ± 755 | 1,887 ± 803 | <0.001 |
|
|
LDL-C, low-density lipoprotein cholesterol; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; AF, atrial fibrillation; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; HbA1c, glycated hemoglobin; Cr, creatinine; Apo, apolipoprotein.
|
